CDY 1.43% 7.1¢ cellmid limited

Ann: Significant New Findings Published on Midkine, page-17

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 118 Posts.
    lightbulb Created with Sketch. 7
    Many posters including Siren4 explained it very well.

    For me, i can't find Evolis in many major  pharmacies(chemist warehouse for example) and the lack of marketing within Australia concerns me. I don't expect it will be a great sales success elsewhere if they can't even get their act together within the domestic market. I don't think the product is a dud but i don't see any improvements to the product since it was originally marketed. Capability to market and decision making around that is well documented(Ikon case for example).

    On biotech side, it's all smoke and mirrors and I don't see anything advanced to clinical trials yet.

    Happy to stand corrected.


    Last edited by tomchena: 08/02/19
 
watchlist Created with Sketch. Add CDY (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.